УКР  |  ENG

Клинические исследования в Украине

Форум Пациентам

Исследования / № 00580125

Описание
Краткое названиеDose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
Полное названиеA Phase 2, Multicenter, Double-Blind, Randomized, Fixed Dose, Parallel Group, 3-Week Inpatient Treatment Study To Evaluate The Dose-Response Relationship, Safety, Efficacy, And Pharmacokinetics Of PF-00217830 Compared With Placebo, Using Aripiprazole As A Positive Control, In The Treatment Of Acute Exacerbation Of Schizophrenia
СпонсорPfizer
Industry
ИсточникPfizer
Под контролемUnited States: Food and Drug Administration
No
Краткое описаниеThe objective of this study is demonstrate efficacy and a dose-response in the treatment of
acute exacerbation of schizophrenia in comparison to placebo.
СостояниеЗавершено
Дата началаNovember 2007
ФазаPhase 2
Вид исследованияAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Набор0
КритерииInclusion Criteria:

Key inclusion criteria include:

- Have a current diagnosis of schizophrenia.

- Increase in symptoms over the past 2-4 weeks.

- Willing to remain inpatients for the duration of the trial.

Exclusion Criteria:

- Subjects with a current DSM-IV axis I diagnosis other than schizophrenia

- Subjects who meet the DSM-IV criteria for psychoactive substance abuse and dependence

- Subjects with a history of treatment resistant schizophrenia

- Females of childbearing potential
ПолBoth
Минимальный возраст18 Years
Максимальный возрастN/A
УсловиеSchizophrenia
Применяемое лечение
DrugPF-00217830
OtherPlacebo
DrugAripiprazole
DrugPF-00217830
DrugPF-00217830
Контакты и расположение
Simferopol , 95006Pfizer Investigational Site
Dnipropetrovsk , 49115Pfizer Investigational Site
Donetsk , 83037Pfizer Investigational Site
Kharkiv , 61068Pfizer Investigational Site
Kharkiv , 61018Pfizer Investigational Site
Kiev , 02660Pfizer Investigational Site
Kyiv , 01030Pfizer Investigational Site
Lugansk , 91045Pfizer Investigational Site
2011 © Клинические испытания в Украине